Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
Recruiting now · Not applicable
Conditions studied: Amyotrophic Lateral Sclerosis
In brief
Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy and blood sampling will be performed at the initial visit (M0), then at M12 (+/- 2 months) for patients, and at M36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. The aim of this research is to model ALS pathology using fibroblasts derived from the patients' skin biopsies.
Key facts
- Study ID
- NCT06450691
- Run by
- Assistance Publique - Hôpitaux de Paris
- People needed
- 110
- Starts
- 2025-08-28
- Expected to finish
- 2034-09-01
- Last updated by the study team
- 2026-04-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- with a known skin disease (acne, atopic dermatitis, psoriasis, melanoma, skin carcinoma, rosacea, scabies; as referenced on http://dermato-info.fr/), which in the investigator's opinion constitutes a contraindication to skin biopsy
- have a platelet count of less than 75,000/mm3 in a laboratory test less than 3 months old,
- with a proven allergy to lidocaine or prilocaine,
- Pregnant or breast-feeding women, or subjects under guardianship, curatorship or safeguard of justice.
- Patient's condition which, in the opinion of the investigator, is incompatible with skin sampling or participation in the study.
- Participation in a clinical trial (involving a drug) or other interventional research if this interferes with FIBRALS research.
Where it is running
- CIC Neurosciences — Paris, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.